Clinical Intelligence
Make medication risk visible — and make the review more structured.
IntractMD combines interaction analysis, polypharmacy stratification, anticholinergic/CNS considerations and deprescribing workflow support.
IntractMD combines interaction analysis, polypharmacy stratification, anticholinergic/CNS considerations and deprescribing workflow support.
Evaluate a regimen across multiple risk factors rather than relying only on individual drug-pair alerts.
Analyze drug-drug, drug-supplement and drug-food interaction concerns together.
Make cumulative anticholinergic exposure part of the medication-review conversation, including OTC products when entered.
Surface medications appearing in published criteria and model hypothetical removal scenarios for clinical review.
Move from risk identification to structured review, patient communication in English or Spanish, and follow-up.
Generate confidence-tiered email, SMS and call-script drafts in English or Spanish to support pharmacist and case-manager workflows.
IntractMD distinguishes established clinical findings from signals calculated across the complete medication profile and AI-assisted predictions. This helps clinicians understand not only what the platform found, but also how confidently the finding should be interpreted.
Supported by authoritative medication information, recognized interaction references, labeling or published clinical criteria. These findings can be presented directly with their supporting evidence.
Derived from the patient's overall medication regimen, including cumulative risk factors such as polypharmacy, CNS burden and other pharmacological dimensions.
AI-assisted analysis can identify potential medication-risk patterns that may not appear as a single established interaction. Predictive findings are labeled as potential and require qualified clinical review before action.
The CPRS is a 0–100 composite risk index designed to summarize multiple pharmacological dimensions across a medication regimen. Current Resolve Medical methodology describes eight dimensions:
Anticoagulant, antiplatelet & additive bleeding effects
QT prolongation, arrhythmia & other cardiac effects
Sedation, respiratory depression & CNS effects
Overlapping serotonergic effects & syndrome potential
Small changes that can increase toxicity risk
Enzyme inhibition, induction & altered exposure
Clearance, accumulation & organ-function considerations
Additive or opposing effects across medications
No significant risks identified
Minor interactions, routine monitoring
Active monitoring needed
Consider regimen modification
Urgent clinical review warranted
The deprescribing workflow evaluates medications against published criteria — AGS Beers Criteria®, STOPP/START v3 and CMS Star Ratings medication-safety measures — and can model a hypothetical medication-removal scenario, recalculating the CPRS for each. Every candidate is shown with the criterion it came from and a link to the source. The result is intended to help a pharmacist or prescriber decide where further review may be warranted.
Review the clinical evidence, data sources, methodology and limitations that inform IntractMD.